中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
菜单
CRO Services
Drug Development Expertise Empowering Research Services for Biologics

Early-Stage Antibody Developability Assessment

Micro Developability Services: High-Throughput Developability Assessment for Lead Optimization

 

Most therapeutic antibody candidates are initially screened and selected based on affinity and functionality, while other important developability factors often receive less attention. This increases unexpected risks at later stages when the candidates are narrowed down, leading to costly re-engineering or program failure. Our antibody developability assessment brings these evaluations earlier in discovery using high-throughput (HTP) assays to assess key attributes such as sequence liability, PK, biophysical properties, stability, and manufacturability. This rapid, HTP, low-material workflow delivers clear, actionable data to support lead optimization, enable early risk assessment, and help projects progress more smoothly toward CMC development.

 

 

 

Early Developability Assessment
Rapid, high-throughput in vitro assays
Minimal Materials Required
<1 mg antibody for most assays
Build Your Own Package
Expert-guided, fit-for-purpose panel for lead optimization

 

Get a Free Consultation

 

Early-stage antibody developability assessment using high-throughput assays and minimal materials to enable early risk assessment and lead optimization in drug discovery.

Our Early-Stage Antibody Developability Assessment Includes:

 

  • In silico analysis: Assesses sequence liability and CDR hotspots, aggregation risks, and immunogenicity.
  • Poly-specificity / PK assessment: Employs high-throughput assays, including AC-SINS, BVP/DMA/insulin ELISA, FcRn affinity, and serum stability studies.
  • Manufacturability assessment: Enables biophysical characterization of proteins via LC-MS and DSF, and stability testing through forced degradation studies.

 

 

Early-stage antibody developability assessment workflow illustrating high-throughput in vitro screening assays with minimal materials, and manufacturability evaluation to support lead optimization.

 

Micro Developability Service Details:

In Silico Analysis Poly-Specificity / PK-Assessment Assays Manufacturability Assessment
  • Sequence liability
  • Immunogenicity
  • Aggregation
  • AC-SINS (self-interaction)
  • BVP/DNA/Insulin ELISA (poly-reactivity)
  • FcRn affinity (half-life)
  • Serum stability (cleavage)

Forced degradation studies (thermal, low pH, freeze-thaw):

  • SEC
  • iCIEF
  • CE-SDS (NR/R)
  • Peptide mapping
  • SPR

Biophysical characterization:

  • DSF/DSC (Tm, Tagg)
  • Solubility/Viscosity for high concentration
  • DLS

Mass Spectrometry:

  • Intact MS (clipping)
  • CIEF-MS (charge variants)
  • Peptide mapping (PTMs)
  • Disulfide/Glycan analysis

 

Note: For custom package or special requirement, please contact our experts for details.

 

Build Your Early Developability Panel with Our Experts

 

 

Case Study #1: AC-SINS (Affinity-Capture Self-Interacting Nanoparticle Spectroscopy) Assesses Antibody Self-Association, Aggregation, and Viscosity

 

AC-SINS is a high-throughput assay used to evaluate antibody self-association and aggregation risks with low sample concentrations. In combination with HIC, it also supports developability assessment of conformational changes in native protein forms, providing insight into viscosity-related behavior and enabling early risk assessment and lead optimization in drug discovery.

 

AC-SINS in vitro assay evaluates antibody self-association and aggregation risks using a high-throughput, low-sample workflow to support early risk assessment.

 

Figure 1: AC-SINS captures antibodies using coated gold nanoparticles to evaluate self-association and aggregation risk at low concentrations. The assay generates an AC-SINS score that helps differentiate well-behaved antibodies from self-associated candidates. Developability assessment data generated through our assay is typically consistent with published results for diverse antibodies to support early risk assessment during discovery.

 

 

Case Study #2: High-Throughput Baculovirus (BVP)/DNA/Insulin ELISA for Assessing Charge-Based and Non-Specific Binding Risks

 

BVP/DNA/Insulin ELISA is a high-throughput, cost-effective assay to evaluate non-specific, low-affinity, charge-based interactions of monoclonal antibodies. This assay provides a reliable indicator of poly-reactivity, generating actionable antibody developability data to prioritize candidates with more favorable profiles during discovery.

 

BVP/DNA/insulin ELISA for early-stage antibody developability assessment showing charge-absed and non-specific binding risks in early discovery.

 

Figure 2: In Panel A, mAb1 and mAb2 display concentration-dependent binding to BVP, DNA, and insulin, indicating high non-specific binding risks, while mAb3 shows minimal poly-reactivity. In Panel B, a panel of clinical monoclonal antibodies was assessed and normalized to a WuXi Biologics positive control, revealing diverse developability assessment profiles to support lead optimization.

 

Need Help Building Your Early Developability Panel?

 

 

Case Study #3: Forced Degradation Studies for Fit-for-Purpose Early Stability Assessment

 

Forced degradation studies evaluate antibody stability profiles under low-pH hold, freeze-thaw, and thermal stress (40 °C) conditions, using analytics such as iCIEF, SEC, CE-SDS, and LC-MS. This workflow supports early manufacturability assessment using limited materials, enabling efficient candidate ranking and selection.

 

Stability testing using forced degradation studies showing low-pH hold, freeze-thaw, and thermal stress results measured by iCIEF, SEC, and CE-SDS.

 

Figure 3: Antibody samples were subjected to low-pH hold, freeze-thaw cycling, and thermal stress at 40 °C, with measurements collected at time zero (T0) and at the endpoint. iCIEF was used to monitor acidic, main, and basic charge variants, SEC assessed monomer purity and aggregation, and CE-SDS under non-reducing (NR) and reducing (R) conditions evaluated fragmentation. Bar charts illustrate changes in acidic species, main peak, and basic variants between T0 and endpoint, supporting developability assessment of therapeutic antibodies to guide engineering and optimization.

 

 

Case Study #4: Data-Driven Antibody Engineering Guided by Early-Stage Developability Assessment

 

With multiple successful projects, our team demonstrates extensive expertise in optimizing challenging antibody candidates. The examples below highlight how early antibody developability assessment and targeted optimization strategies enable improved molecular properties and smoother progression toward CMC readiness.

 

Early-stage antibody developability assessment showing improved expression, reduced aggregation and non-specific binding, enhanced thermal stability, and extended PK-related performance.

 

Figure 4: Initial early-stage developability assessment identified downstream risks, such as low expression yield, degradation, non-specific binding, thermal instability, aggregation, and suboptimal PK-related characteristics. Guided by these insights, targeted antibody engineering was implemented to address them. Comparative results demonstrate improved expression yield, reduced degradation, elimination of non-specific binding, enhanced thermal stability, reduced aggregation, and extended PK-related performance. These data highlight the importance of early assessment to reduce downstream development risks and guide efficient lead optimization.

 

Start Your Early Developability Assessment

 

Frequently Asked Questions for our Micro Developability Services

Q: How should early-stage developability asessment be integrated into bispecific/TCE projects?

We recommend a staged workflow that aligns developability screening with format decisions. First, light triage of parental mAbs remove obvious developability risks and reduce downstream pairing complexity. Next, design and generate bispecific/TCE formats using a focused subset of qualified parental antibodies. Then, apply Micro Developability assessment to the bispecific candidates, where format-specific liabilities can be more accurately evaluated and prioritized for optimization.

Q: Have you observed any degradation of the His tag in vivo? Could this impact the detection of molecules in PK assays?

During stage 2 development, when evaluating 50 to 100 molecules, degradation trends are generally consistent across candidates, making comparative assessments more relevant than individual evaluations. In a VHH-based example, instability was primarily attributed to the inherent poor stability of the VHH itself rather than degradation of the His tag. For cases involving only one or two His-tagged molecules, a thorough understanding of the molecule is essential to assess potential impacts on PK analysis. If His tag degradation is a concern, targeted proteomics offers an alternative approach, enabling peptide digestion and direct targeting without relying on His tag-based immunoprecipitation. 

Q: Are most of your developability case studies related to IgG1? Do study outcomes apply to other subclasses (e.g., IgG2, IgG3, IgG4)?

Yes, most of our data focus on IgG1, as it serves as a well-established benchmark for later-stage development and manufacturing. IgG2 is less commonly used due to the risk of disulfide bond scrambling, which can be identified through in silico analysis. IgG3 is also less prevalent. Our assays have been applied to bispecific antibodies, Fc fusion proteins and other modalities, demonstrating similar trends across these formats. 

Q: Have you used any methods besides Mass Spec to analyze serum stability results?

Yes, we have compared the data with ELISA. However, ELISA has certain limitations, particularly in reproducibility. In contrast, Mass Spec offers higher sensitivity, enabling detection at concentrations as low as 0.5 mg/mL. 

Q: Can in vitro serum incubation predict in vivo stability?

In vitro serum incubation can indicate potential stability risks but does not fully correlate with in vivo stability. In vivo degradation involves both direct degradation and protein recycling pathways, which cannot be entirely replicated in vitro. Using both assays allows for a comparative assessment, but due to the high cost, in vivo studies are typically reserved for later development stages. 

Q: Do you verify binding and PTMs during the developability stress test?

Yes, verifying binding and PTMs during stress testing is beneficial, like under thermal stress, freeze-thaw, and low pH conditions. However, early-stage assessments are often limited by material availability and the large number of candidates (e.g., 50–100 molecules). At later stages, PTM testing under stress conditions is recommended to ensure stability and mitigate risks before entering CMC development. Proper timing of these evaluations is crucial for optimizing resource use and ensuring robust candidate selection. 

Q: Do study results using transiently produced mAbs closely align with those from stable cell lines?

For most early-stage assessments, such as AC-SINS, heat hydrophobicity, and charge distribution, the choice of cell line has minimal impact, making transiently produced mAbs suitable for evaluation. However, PTMs are highly dependent on the cell line and culture conditions, so final assessments should be performed using stable cell lines. Additionally, WuXi Biologics utilizes the same parental cell line for both transient and stable pool production, ensuring greater consistency in key attributes, particularly glycosylation, and enhancing the reliability of early-stage assessments. 

Q: Why is high pH hold testing less critical than low pH hold?

High pH hold testing is typically recommended in later development stages but is less prioritized early on due to limited material availability and its lower relevance compared to low pH hold or freeze-thaw studies. 

Q: How do you determine whether a peak decrease is due to actual degradation or stress during immunoprecipitation?

To differentiate real degradation from immunoprecipitation-induced stress, we assess protein recovery before and after immunoprecipitation, ensuring over 95% recovery. Additionally, we incorporate an internal control, such as Herceptin, in our experiments. If Herceptin shows no decrease, we can confidently conclude that the immunoprecipitation process is functioning as expected and not contributing to protein degradation. 

Q: How much antibody is needed for each protein characterization assay?

A: We only require a small amount of antibody for each assay. Approximately 1 mg of antibody is sufficient for most assays except for forced degradation and stability studies. Specific requirements needed for each assay are detailed in the above table.

Q: What does a change in iCIEF percentage indicate for the 40°C sample?

A: The change in iCIEF percentage shows alterations in the distribution of main, acidic, and basic protein species. High-temperature stress causes these changes mainly due to post-translational modifications (PTMs) and chemical alterations, like deamidation and oxidation, which can alter the charge properties of these protein species.

Q: Can you briefly introduce your in silico analysis service?

A: Our in silico analysis includes three main categories: sequence liability, aggregation propensity, and immunogenicity prediction. Sequence liability uses an open-source algorithm to predict PTMs that might affect antigen-binding in the complementarity-determining regions (CDRs). Aggregation propensity is assessed based on the solvent-accessible surface area of hydrophobic residues and the presence of free cysteine, categorizing potential aggregations as high, medium, or low. It’s important to note that the formation of protein aggregates is affected by several factors, including the solvent micro-environment, concentration, storage time, and storage conditions. So, our predictions only reflect the potential impacts of hydrophobicity and unwanted disulfide bonds. Lastly, our immunogenicity prediction demonstrates approximately a 0.6 correlation between the generation of anti-drug antibodies (ADA) and our predictions, which are based on publicly available data.

Q: What in silico tools do you use for aggregation profiling? Is this open source or proprietary?

A: We use a proprietary algorithm for aggregation profiling. It analyzes the solvent-accessible surface region of hydrophobic residues and the presence of free cysteine from structural information.

Q: Do you conduct high pH hold for forced degradation studies?

A: Yes, we can perform high pH hold conditions upon request for forced degradation studies.

Q: How do you determine if observed degradation in serum stability assays is due to incubation in serum or stress from capture/elute post-incubation?

A: We use Herceptin as a control in serum stability assays. By comparing the percent intensity of each sample at 48 hours and 96 hours to Herceptin’s percent intensity, we determine if the degradation is systematic or specific to the sample.

Q: What is the throughput of your Micro Developability platform?

A: Our Micro Developability platform typically handles about 100 molecules but can easily accommodate several hundred if necessary.

Q: What is the typical turnaround time for your full Micro Developability package?

A: We can complete most of our pharmacokinetic-predicting assays within two weeks. The duration for forced degradation studies varies based on the conditions requested, and it typically takes an additional 1-2 weeks to generate the final report after experiments conclude.

Q: What instruments do you use for TM measurements?

A: For TM measurements, we have two main options: Differential Scanning Fluorimetry (DSF) and Differential Scanning Calorimetry (DSC). DSF is a more cost-effective choice while DSC is more expensive. The selection depends on your specific needs.

Q: For AC-SINS assays, do you only test antibodies with human Fc domain?

A: Most of the samples tested are human antibodies, and we have a default stock of AuNP for human antibody measurements. We can also adapt to customized species, such as mouse or canine. Please inform us in advance so that we can prepare the corresponding reagents to produce customized AuNP.

Q: Why are AC-SINS results related to pharmacokinetics (PK) predictions?

A: Molecules prone to self-association or aggregation suggests fast clearance in vivo and can be predicted through AC-SINS.

Q: Why are Baculovirus (BV), DNA, and Insulin chosen? How is the ELISA score evaluated?

A: DNA and Insulin: These were adapted from assays identifying autoreactive antibodies in lupus patients and are highly sensitive in detecting charge-based, low-affinity, or above-background off-target binding (DOI: 10.1080/19420862.2017.1417718 and 10.1080/19420862.2015.1016696).

 

BV Virions: These stable particles mimic infected cell surfaces, presenting a complex mixture of phospholipids, carbohydrates, glycoproteins, extracellular matrix and nucleic acids, as well as the viral capsid. This allows for the detection of various interactions, such as electrostatic and hydrophobic interactions.

 

The ELISA score of each sample is the percentage referenced to our positive control mAb, which has fast clearance in actual PK studies. Thresholds for low, medium and high risk are set based on publications from pharmaceutical companies, such as Pfizer and Genentech as well as our own experience.

Q: Why is mouse serum selected for serum stability studies?

A: Mouse serum is used because it aligns with animal study results. The components in the mouse matrix are different from human antibody Fc-domains, which is beneficial for target antibody enrichment in the mouse serum. However, IgG depleted human serum will be up and running very soon!

More FAQs

Your Project. Our Expertise.

Contact Us